NCT01998126View on ClinicalTrials.gov

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 2, 2013

Primary Completion Date

May 9, 2017

Study Completion Date

March 29, 2018

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Ipilimumab

Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)

DRUG

Erlotinib

Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)

DRUG

Crizotinib

Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)

DRUG

Nivolumab

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Utah

OTHER

NCT01998126 - Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter